top of page

Leading the Way in Protein-Based Diagnostics

Sunbird Bio is developing protein-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer’s disease, other neurological disorders and early-stage cancer.
Sunbird Bio Icon

We are the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer's disease, with a simple blood draw.

Our APEX technology has demonstrated potential to provide researchers and clinicians with actionable information that is not available or accessible from current diagnostics. The growing availability of medications developed to slow progression of this irreversible disease increases the importance of accurate and timely diagnosis and monitoring for all patients.

Neurodegenerative diseases such as Alzheimer’s are notoriously difficult to diagnose and treat, with devastating consequences for patients and their families. APEX is the only test currently in development that could help address the tremendous, growing need for more sensitive, reliable, non-invasive diagnostic tests to accelerate drug development and enhance patient care.

Sunbird Bio APex Technology.png

Our Technology

The validated APEX technology platform has demonstrated breakthrough potential to dramatically improve standards of care in Alzheimer’s disease and other neurological disorders.


Our Focus

Alzheimer’s disease is among the most prevalent illnesses worldwide. A lack of accessible and reliable diagnostics is hindering diagnosis and treatment.


About Us

Sunbird Bio is a leader in protein diagnostics, driving paradigm-shifting success and improved patient outcomes through our novel platforms.


PET imaging, the current gold standard, is expensive, often inaccessible and not scalable

Molecular diagnostics use cerebrospinal fluid (CSF) obtained through painful, expensive and invasive procedures

Cognitive behavioral assessment is subjective, unreliable and can’t distinguish early stages of disease

Up to 40 million people worldwide are living with Alzheimer’s disease.

Due largely to diagnostic limitations, 50% of these individuals will never receive a referral to a neurologist or memory care specialist.

While early detection of Alzheimer’s disease has substantial clinical benefits and can empower affected individuals and their care partners to make proactive decisions about future treatment and care, currently available diagnostic tests may impede early diagnosis and monitoring of disease progression. 


Data from a landmark study show that the APEX test has a 90% correlation to gold-standard PET, while all other blood-based diagnostic tests have a correlation of about 20%.

bottom of page